PharmacofMRI of Anxiolytic Medications (Pregabalin)

Overview

The purpose of this study is to use functional magnetic resonance imaging (fMRI) in healthy controls to examine the acute effects of certain anxiolytic medications on brain function. In this case, the medication pregabalin will be used. The investigators hypothesize that pregabalin (at doses of 50 mg and 200 mg, versus placebo) will yield a reduction in amygdala and insula activity (in a dose-dependent fashion) during emotion processing using fMRI.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Diagnostic
    • Masking: Single (Participant)
  • Study Primary Completion Date: December 2008

Detailed Description

Increased amygdala and insula activity have been implicated in neurobiological models of anxiety. Using fMRI, the anxiolytic medication, lorazepam, has previously been found to decrease activation in these areas during the processing of emotional stimuli. This study aims to replicate those results but by using a different medication, pregabalin. An eventual aim of this study, in combination with future studies, is to evaluate the utility of fMRI as a tool to identify anxiolytic function in both established and novel compounds that may be used to treat anxiety.

Interventions

  • Drug: Pregabalin 50mg
    • One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan
  • Drug: Pregabalin 200 MG
    • One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan
  • Drug: placebo
    • One dose of matched oral placebo to be administered one hour prior to fMRI scan

Arms, Groups and Cohorts

  • Active Comparator: Pregabalin 50 mg
    • Pregabalin oral tablets (50 mg)
  • Active Comparator: Pregabalin 200 mg
    • Pregabalin oral tablets (200 mg)
  • Placebo Comparator: Placebo
    • Placebo

Clinical Trial Outcome Measures

Primary Measures

  • Effect of Pregabalin (Two Doses) Versus Placebo
    • Time Frame: Week 1, 2, 3 (Cross-over Design)
    • Region of Interest (ROI) analysis of contrast of doses (high and low) of pregabalin vs placebo on brain activity at rest and during emotional stimuli using fMRI and clinical scales.

Participating in This Clinical Trial

Inclusion Criteria

  • Male, or female (not pregnant or intending to become pregnant during the study) – Between the ages of 18-30. – In good general health. – No specific contraindications to the drug being administered Exclusion Criteria:

  • Subjects with a history of DSM-IV depressive disorder, psychotic disorder, anxiety disorder – Subjects who meet criteria for substance abuse or dependence within the last 6 months – Subjects with an positive urine screen for illicit drugs having clinically significant abnormal laboratory, ECG or physical examination findings not resolved by the baseline visit – Patients who have taken psychotropic drugs or antidepressants (including monoamine oxidase inhibitors, MAOI's) within the last year – Subjects who are left-handed. – Subjects suffering suffers from claustrophobia, or phobia for injections or blood – Magnetic Resonance Imaging related exclusion criteria:

cardiac pacemaker, metal fragments in eyes/skin/body (shrapnel), subjects who have ever been a metal worker/welder; history of eye surgery/eyes washed out because of metal, aortic/aneurysm clips, prosthesis, by-pass surgery/coronary artery clips, hearing aid, heart valve replacement, subjects who are in the first trimester of pregnancy, subjects with an I.U.D. (birth control device), a shunt (ventricular or spinal), electrodes, metal plates/pins/screws/wires, or neuro/bio-stimulators (TENS unit).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 30 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of California, San Diego
  • Collaborator
    • National Institute of Mental Health (NIMH)
  • Provider of Information About this Clinical Study
    • Principal Investigator: Murray B. Stein, Professor – University of California, San Diego
  • Overall Official(s)
    • Murray B Stein, MD, MPH, Principal Investigator, University of California, San Diego

Citations Reporting on Results

Aupperle RL, Ravindran L, Tankersley D, Flagan T, Stein NR, Simmons AN, Stein MB, Paulus MP. Pregabalin influences insula and amygdala activation during anticipation of emotional images. Neuropsychopharmacology. 2011 Jun;36(7):1466-77. doi: 10.1038/npp.2011.32. Epub 2011 Mar 23.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.